Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, focusing on how contemporary therapeutic choices in metastatic hormone-sensitive ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with ...

A new international study has found that combining two cancer medicines may significantly slow the growth of a dangerous form of prostate cancer in some men. The research was led by scientists at ...

Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Monte Rosa (GLUE) shares rise as it teams with Johnson & Johnson to test MRT-2359 + ERLEADA in mCRPC AR mutations in a Phase ...

Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...

U.K. surgeons remotely removed a man’s prostate cancer from 1,500 miles away in the country’s first successful robot-assisted telesurgery.